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Abstract
Background: Oncological health care services are challenged by the increasing number of cancer survivors, long-term follow-up
care, and fragmentation of care. Digital care platforms are potential tools to deliver affordable, patient-centered oncological care.
Previous reviews evaluated only one feature of a digital care platform or did not evaluate the effect on enhancement of information,
self-efficacy, continuity of care, or patient- and health care provider–reported experiences. Additionally, they have not focused
on the barriers and facilitators for implementation of a digital care platform in oncological care.
Objective: The aim of this systematic review was to collect the best available evidence of the effect of a digital care platform
on quality of care parameters such as enhancement of available information, self-efficacy, continuity of care, and patient- and
health care provider–reported experiences. Additionally, barriers and facilitators for implementation of digital care platforms
were analyzed.
Methods: The PubMed (Medline), Embase, CINAHL, and Cochrane Library databases were searched for the period from
January 2000 to May 2020 for studies assessing the effect of a digital care platform on the predefined outcome parameters in
oncological patients and studies describing barriers and facilitators for implementation. Synthesis of the results was performed
qualitatively. Barriers and facilitators were categorized according to the framework of Grol and Wensing. The Mixed Methods
Appraisal Tool was used for critical appraisal of the studies.
Results: Seventeen studies were included for final analysis, comprising 8 clinical studies on the effectiveness of the digital care
platform and 13 studies describing barriers and facilitators. Usage of a digital care platform appeared to enhance the availability
of information and self-efficacy. There were no data available on the effect of a digital care platform on the continuity of care.
However, based on focus group interviews, digital care platforms could potentially improve continuity of care by optimizing the
exchange of patient information across institutes. Patient-reported experiences such as satisfaction with the platform were
considerably positive. Most barriers for implementation were identified at the professional level, such as the concern for increased
workload and unattended release of medical information to patients. Most facilitators were found at the patient and innovation
levels, such as improved patient-doctor communication and patient empowerment. There were few barriers and facilitators
mentioned at the economic and political levels.
Conclusions: The use of digital care platforms is associated with better quality of care through enhancement of availability of
information and increased self-efficacy for oncological patients. The numerous facilitators identified at the patient level illustrate
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that patients are positive toward a digital care platform. However, despite these favorable results, robust evidence concerning the
effectiveness of digital care platforms, especially from high-quality studies, is still lacking. Future studies should therefore aim
to further investigate the effectiveness of digital care platforms, and the barriers and facilitators to their implementation at the
economic and political levels.
(J Med Internet Res 2021;23(9):e28869) doi: 10.2196/28869
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Introduction
Background
Over the past few decades, the management of patients with
cancer has considerably changed. Owing to earlier detection of
cancer and improved treatment strategies, the number of cancer
survivors has increased [1]. For this reason, patients with cancer
currently require long-term follow-up care, similar to patients
with chronic diseases. It is expected that the increased need of
follow-up care, in combination with an overall increase of cancer
patients due to an aging society, will intensify the use of health
care services and increase health care costs [2]. Current health
care systems cannot accommodate these increased demands and
are deemed unsustainable [3,4]. An additional problem that
requires a reevaluation of oncological health care services is
the multidisciplinary, and sometimes multi-institutional, aspect
of current care. This refers to the fact that cancer patients are
usually cared for by multiple health care providers (HCPs), and
that, as a result of centralization of complex care to high-volume
centers [5], patients may receive parts of their treatment in
multiple hospitals [6-9]. These aspects result in the
fragmentation of cancer care [10].
The challenges facing cancer care are recognized by the World
Health Organization [11] and the Health Program of the
European Union [12], and have prompted them to think of
different health care structures that enable the delivery of
affordable, coordinated, patient-centered oncological care. A
solution in restructuring health care for oncological patients
could be found in telemedicine or electronic health (eHealth).
Moreover, the COVID-19 pandemic, which led to the sudden
forced implementation of telemedicine, has demonstrated the
potential of telemedicine and eHealth to many patients and
doctors [13]. These technologies therefore seem to be
indispensable for sustainable care.
For these reasons, the time seems right to deploy eHealth much
more widely in oncological care. An updated, accepted
definition of eHealth is lacking, but eHealth can be perceived
as an umbrella term for all digital communication and
information technologies that aid in health care or health care
services [14,15]. Over the past decades, multiple eHealth
interventions have been developed to support oncological care
[16,17]. The eHealth-based intervention of interest in this review
is a digital care platform. We define a digital care platform as
an eHealth-based tool that aims to increase coordinated and
patient-centered care. A digital care platform incorporates
several different features, which separately have been the subject
of study elsewhere [18-21]. First, digital care platforms may
provide patients with information specific to their situation.
Second, they can provide an overview of the patients’ personal
health records, including appointments, medical results, and
correspondence. Third, digital care platforms may also offer
direct, secure messaging with HCPs (eg, electronic consultation
[e-Consult]). We consider these three characteristics as key
features of a digital care platform. Some additional features may
include the registration of patient-reported outcomes (PROMs),
a patient forum, the possibility to exchange patient-related
information between different health care institutes, and enable
communication between HCPs and general practitioners.
Studies on the use of eHealth-based tools and their effect on
care processes have been previously described for patients with
chronic diseases [22,23]. A recent systematic review by Tighe
et al [23] indicated that digital platform–like interventions such
as self-management tools have a positive effect on physical
activity and disease-related quality of life. A systematic review
by Kooij et al [22] indicated that digital interventions had
positive effects on patient confidence and HCP satisfaction, but
that firm conclusions on its clinical effects could not be drawn.
Studies on the use of eHealth in oncological care have reported
favorable results, as it has been associated with improved
patient-provider communication [24]; improved coping with
cancer-related symptoms such as fatigue, depression, anxiety,
and physical activity [16,25-28]; and improved medication
adherence and higher patient satisfaction [20,27]. Some studies
have also reported favorable effects on quality of life [29,30].
However, these studies investigated the effect of only one
feature of a digital care platform, for instance the registration
of PROMs. Previous reviews did not study the digital care
platform as a central part of the oncological health care service
or the effect of digital care platforms on enhancement of
information, continuity of care, or patient- and HCP-reported
experiences. The effect on patient self-efficacy has only been
studied for one feature of a digital care platform, namely
self-management programs [25]. The outcome parameters of
interest (ie, enhancing availability of information, self-efficacy,
continuity of care, and patient-reported and HCP-reported
experiences) can also be placed in the Quality of Care
framework provided by the Institute of Medicine [31]. The six
domains of quality of care are safe, effective, patient-centered,
timely, efficient, and equitable care. Enhancing availability of
information is a measure of effective and equitable care,
self-efficacy is a measure of patient-centered care,
patient-reported and HCP-reported experiences are measures
of safe and patient-centered care, and continuity of care is a
measure of efficient care and arguably also timely care.
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Additionally, we did not identify any existing systematic reviews
that focused on the barriers and facilitators that exist for the
successful implementation of a digital care platform in
oncological care. This is important to assess so as to adequately
determine the feasibility of a digital care platform as part of
routine oncological care.
Objectives
The aim of this systematic review was two-fold: (1) to collect
the best available evidence of the effect of a digital care platform
on quality of care for oncological patients by focusing on
enhancement of available information, self-efficacy, continuity
of care (including communication), and patient-reported and
HCP-reported experiences; and (2) to analyze the currently
reported barriers and facilitators for implementation of a digital
platform in oncological health care.
Methods
Protocol and Registration
This systematic review protocol was registered with the
International Prospective Register of Systematic Reviews
(PROSPERO; registration number CRD42020199282) [32] and
was carried out according to the PRISMA (Preferred Reporting
Items for Systematic Review and Meta-Analyses) guidelines
[33].
Search Strategy
The PubMed (Medline), Embase, CINAHL, and Cochrane
Library databases were searched for the period from January 1,
2000 until May 27, 2020. Search terms used included
“neoplasms” and affiliated terms combined with “patient portal”
or “digital care” or “eHealth.” The aim of this search query was
to provide search results on literature involving both the effect
of a digital care platform on quality of care for oncological
patients as well as barriers and facilitators for implementation.
The exact search query is shown in Textbox 1.
Textbox 1. Search query.
(neoplasms [mesh] OR cancer* [tiab] OR tumor* [tiab] OR tumour* [tiab] OR neoplasm* [tiab] OR malignan* [tiab])
AND
(“Patient Portals”[Mesh] OR “Telemedicine” [Mesh] OR Patient portal*[tiab] OR Patient platform*[tiab] OR Patient web portal*[tiab] OR Patient
internet portal*[tiab] OR virtual care*[tiab] OR digital care [tiab] OR ehealth [tiab] OR e-health [tiab] OR econsult [tiab] OR e-consult [tiab])
Eligibility Criteria
Studies of interest included randomized controlled trials (RCTs),
prospective studies, and retrospective cohort studies. In addition,
qualitative studies in which questionnaires were distributed or
stakeholders were interviewed to investigate barriers and
facilitators were also included. All studies were required to
generate empirical data. Studies not written in English were
also screened on the condition that they presented an English
abstract. A translator could translate the full text if the abstract
seemed to be eligible, thus avoiding a language bias. Systematic
and narrative reviews, conference abstracts, and single case
reports were excluded.
For our first objective, to collect the best available evidence of
the effect of a digital care platform on quality of care, studies
were required to involve oncological patients ≥18 years old.
These clinical studies had to assess the effectiveness of a digital
care platform. Although we provided our definition of a digital
care platform in the Introduction, considering the exploratory
stage of research of digital platforms in oncological care, we
suspected that there would be a rather limited number of studies
investigating such an extensive digital care platform. For this
reason, for inclusion in our systematic review, a digital care
platform was required to have at least two of the following key
features: (1) provide general information concerning the disease
as education (eg, symptoms, treatment, follow-up, prognosis);
(2) provide patient-specific information concerning their medical
file, such as planned appointments, treatments, and lab results;
and (3) enable patients to communicate with their physician or
specialized nurse via chatting, e-Consult, or email. Figure 1
depicts these and other features of a digital care platform.
Studies that did not involve a digital care platform with at least
two of the three above-mentioned features and studies that
provided insufficient or vague details concerning the digital
intervention were excluded from the analysis to assess our
primary objective.
For the second objective, identification of barriers and
facilitators for implementation of a digital care platform in
oncological care, studies were not required to involve a digital
care platform that was already implemented. They could
comprise studies that actually implemented a digital care
platform and subsequently described the barriers and facilitators
for implementation, but they could also comprise studies that
identified barriers and facilitators based on a hypothetical
discussion with stakeholders. In the latter case, the digital care
platform in question was not yet implemented or developed.
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Figure 1. Explanatory illustration of a digital care platform. Studies included in this systematic review were required to investigate a digital care
platform with at least two of the following features: (1) general information provision, (2) electronic patient file, or (3) electronic consult (Econsult)
with health care providers (HCPs). PROM: patient-reported outcome measure.
Study Selection
Two separate reviewers (JH and LV) screened the search output
on titles and abstracts using Rayyan software [34]. During this
screening process, the reviewers were blinded to each other’s
decisions. Studies with a contradictory judgment were discussed.
In case of a remaining discrepancy, senior reviewers (RH and
MS) were asked to arbitrate. The full texts of the selected studies
were screened for eligibility. Reference lists of studies that were
included after full-text screening were checked for additional
eligible studies (snowball method). In cases in which multiple
eligible studies reported on the same dataset (≥50% overlap of
sample size), we excluded the article with the shortest follow-up.
Data Extraction and Analysis
Two authors (JH and LV) extracted data using a shared template.
These data included: (1) author, year of publication; (2) country;
(3) study design; (4) patient population, sample size; (5)
platform that was the subject of the study; 6) features of the
platform; and (7) the outcome parameters, including
enhancement of available information, self-efficacy, continuity
of care, and patient- and HCP-reported experiences. If possible,
data were pooled; otherwise, synthesis of the results was
performed qualitatively.
Barriers and facilitators for implementation of digital care
platforms were categorized according to the framework of Grol
and Wensing [35]. This framework categorizes barriers and
facilitators at six different levels: (1) innovation, which involves
advantages in practice, feasibility, credibility, accessibility, and
attractiveness; (2) individual professional, which concerns the
awareness, knowledge, attitude, motivation to change, and
behavioral routines of the involved professionals; (3) patient,
which involves knowledge, skills, attitude, and compliance of
the patients; (4) social context, which concerns opinion of
colleagues, culture of the network, collaboration, and leadership;
(5) organizational context, which includes the organization of
the care processes, staff, capacities, resources, and structures;
and (6) economic and political contexts, which involve
regulations, financial arrangements, and policies. The frequency
of the barriers and facilitators mentioned, and the quality of the
studies were used to prioritize barriers and facilitators.
Critical Appraisal of Evidence
The Mixed Methods Appraisal Tool (MMAT) version 2018
was used to critically appraise the included studies [36]. The
MMAT is designed to help reviewers appraise the quality of
empirical studies with different methods. These include
quantitative RCTs, quantitative nonrandomized trials,
quantitative descriptive studies, as well as qualitative and mixed
methods studies. Each category includes five different quality
parameters, all requiring to be assessed by answering “yes,”
“no,” or “cannot tell” (maximum total score=5). Two authors
(JH and LV) independently appraised all studies. In case of
disagreement, RH and MS were asked to arbitrate. Studies with
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a total score of 1-2 were considered to be of low quality, a study
with a score of 3 was considered to be of moderate quality, and




The initial search generated 6789 articles. After removal of
duplicates and initial screening of titles and abstracts, 52 studies
remained for full-text assessment. Of these 52 studies, 17 articles
met our eligibility criteria and were included in this systematic
review. Figure 2 depicts the PRISMA flowchart for the study
screening process.
Figure 2. PRISMA flowchart.
Study Characteristics
Overview
Of the 17 included studies, eight were clinical studies that
implemented a digital care platform and assessed its effect on
at least one of the predefined outcome parameters [37-44]. Four
of these clinical studies [39,42-44] also described barriers and
facilitators for implementation. The other nine studies [45-53]
only investigated barriers and facilitators for digital care
platforms. None of the included studies was written in a
non-English language. Table 1 and Table 2 show the baseline
characteristics of the clinical studies and the barrier and
facilitator studies included in this review, respectively.
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Table 1. Baseline characteristics of clinical studies.

















































































aQ1: addresses research question 1 (to collect the best available evidence of the effect of a digital care platform on quality of care for oncological
patients).
bQ2: addresses research question 2 (to analyze the currently reported barriers and facilitators for implementation of a digital platform in oncological
health care).
cEMR: electronic medical record.
de-Consult: electronic consult.
eCOC: continuity of care.
fPRE: patient-reported experiences.
gHCPE: health care provider–reported experiences.
hRCT: randomized controlled trial.
iBCA: breast cancer.
jCHESS: Comprehensive Health Enhancement and Support System.
kNSCLC: nonsmall cell lung cancer.
lPCA: prostate cancer.
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Table 2. Baseline characteristics of barrier and facilitator studies.
Q2bQ1aDescription of platformPatient population and sample sizeStudy designCountryReference
✔XPatient portals offer functional ben-
efits to patients as they enable con-




USAlpert et al [45]
venient patient access to EMRc datan=5, genitourinary n=4, lung n=3,
sarcoma n=3, skin n=3, gynecologic
n=2, other n=3) and 13 oncologists
cancer patients and
oncologists from devices such as personal com-
puters or smartphones; they allow
the ability to request medication re-
fills, schedule appointments, and
they support secure messaging
✔XPatient-controlled “personal electron-
ic health record” (PEPA) (in devel-
opment)
12 colorectal cancer patients, 17
physicians, and 26 other health care
professionals
Qualitative explo-




✔XCMyLife, a web-based, patient-
centered intervention
8 CMLd patients, 14 hematologistsDesign thinking devel-
opment study
NetherlandsEctor et al [47]
✔XNot yet developedPatients with hematologic malignan-
cy (questionnaire: n=204, focus
Mixed methods de-
sign: focus group and
NetherlandsGeerts et al [48]




survey based on litera-
ture
✔XNot yet developed13 nurses from a cancer centerQualitative study us-
ing 2 focus groups
USGerber et al
[49]
✔XInternet-based technologies such as
patient portals, websites, and appli-






cations managed by health care insti-
tutions to improve cancer care coor-
dination
✔XElectronic patient portal accessible
through smartphones (not yet devel-
oped)




CanadaKildea et al [51]
✔XInteractive portal21 BCAe patients, 31 lung cancer





✔XPatient gateway application as pa-
tient portal: a secure, web-based
Focus group: 20 patients and family
and 5 advisory council members;





database enabling patient access to
their health and disease information
embedded within an EMR, managed
by individual health care organiza-
tions and accessible via the internet
✔✔The digital oncology platform in-
cludes the individualized care path,
Interviews with 23 patients, 2
physicians, 1 nurse specialist, 2
Mixed method triangu-
lation design
BelgiumDe Regge et al
[39]
reliable treatment-related informa-nurse consultants, 9 nurses, and 1
psychologist tion, contact details for the treatment
team, secure conversations with the
treatment team, self-registration of
complaints, and a diary
✔✔MyAvL includes personalized edu-
cational material, overview of past
6/92 BCA patients were included in





and upcoming appointments, EMRs,care providers were asked to fill out
a questionnaire
design and focus
group medication overview, questionnaire
concerning PROMsf
✔✔WebChoice is an interactive elec-
tronic health application that in-
103 patients with breast cancer
(n=56) and prostate cancer (n=47)
Prospective cohortNorwayRuland et al
[43]
cludes personalized information, areceived questionnaires with space
communication tool where patientsfor additional comments and sugges-
tions can receive support from peers or
professionals, a diary, and a self-
management component
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Q2bQ1aDescription of platformPatient population and sample sizeStudy designCountryReference
✔✔Healthy.me is a secure personally
controlled health management web-
site that features the patient journey
with tailored information, appoint-
ment overviews, interactive forums,
and messaging with peers and pri-
vate messaging with health care
providers
50 patients with BCA were asked to
use the platform and fill out a ques-
tionnaire; 9 patients were invited for
a face-to-face feedback session
Prospective pilot
study
AustraliaTiong et al [44]
aQ1: addresses research question 1 (to collect the best available evidence of the effect of a digital care platform on quality of care for oncological
patients).
bQ2: addresses research question 2 (to analyze the currently reported barriers and facilitators for implementation of a digital platform in oncological
health care).
cEMR: electronic medical record.
dCML: chronic myeloid leukemia.
eBCA: breast cancer.
fPROM: patient-reported outcome measure.
Study Design
Among the clinical studies, three were RCTs [37,38,41], two
were mixed methods studies [39,42], and three were pilot or
feasibility studies [40,43,44] investigating the use of the
platform in a small cohort. The three RCTs included 450, 167,
and 257 patients, respectively, and all assessed the effectiveness
of different variations of a digital care platform [37,38,41]. For
example, Baker et al [37] assessed the effectiveness of different
components of a digital care platform by comparing patient
groups using a platform with information only; a platform with
information and support; and a platform with information,
support, and coaching. The control group did not use a digital
care platform but used the internet. An example of one of the
mixed methods studies is that performed by Kuijpers et al [42],
in which a digital care platform was implemented in a small
cohort with a postintervention questionnaire, followed by focus
group discussions. Studies solely investigating barriers and
facilitators were mainly qualitative in nature, with the exception
of three studies applying a mixed methods methodology
[48,51,53] and one study using a quantitative methodology [50].
Patient Population
Breast cancer patients formed the majority of the study
population of the clinical studies, with 75% of all studies
including solely this patient population. The patient population
was therefore mostly female, highly educated, and young (mean
age 50 years) [37,38,42,43]. The other studies included patients
with nonsmall cell lung cancer or a diverse group a of cancer
patients such as those with renal cell cancer and sarcoma. One
study [43] included two different patient groups, namely breast
cancer and prostate cancer patients, and compared the use and
effectiveness of the digital care platform between these two
groups. The barrier and facilitators studies (Table 2) included
patients with colorectal cancer, lung cancer, breast cancer,
hematological cancer, and a variety of other cancer types.
Interventions
Within the eight clinical studies, five web-based platforms were
distinguished. These platforms were all web-based and were
not integrated in the electronic medical record (EMR).
Seventy-five percent of the studies assessed a platform that also
intended to improve self-management by, for instance, symptom
monitoring, physical activity advice, or self-therapy
[37,38,40-43]. Although each digital care platform had at least
two of the three predefined criteria, heterogeneity concerning
the platforms was observed. For example, the digital care
platform described by De Regge et al [39] enabled HCPs,
including general practitioners, to read their patients’ medical
records from other health care centers. This allowed them to
gain insight into their patients’ treatment trajectory and
decision-making by other involved HCPs. Other platforms such
as those described by Groen et al [40] and Kuijpers et al [42]
did not have this feature, and provided personalized patient
education material, an overview of upcoming hospital
appointments, and tailored physical activity.
Methodological Quality
Quality assessment of the included studies is shown in Table
3. Of the clinical studies, four studies were of low quality
[37,41,43,44], three of moderate quality [38,39,42], and one
study was assessed as a high-quality study [40]. Regarding the
barrier and facilitator studies, three studies were of low quality
[49,51,53], one of moderate quality [48], and five were of high
quality [45-47,50,52].
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1———————————————????1—————Gustafson et al [41]
Clinical studies with barri-
ers and facilitators
3NYY?YYYYYY——————————YN?YYde Regge et al [39]
3——————————YYNYN——————————Kuijpers et al [42]
1——————————???NY——————————Ruland et al [43]
1——————————?NY?N——————————Tiong et al [44]
  Barrier and facilitator
studies
5————————————————————YYYYYAlpert et al [45]
5————————————————————YYYYYBaudendistel et al [46]
5————————————————————YYYYYEctor et al [47]
3N?YYYY?YYY——————————?N?YYGeerts et al [48]
2————————————————————N??YYGerber et al [49]
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aRCT: randomized controlled trial.
bFor mixed methods studies, a score of 5.5 was required to be evaluated using category 1 and category 3 or 4.






Enhancing Availability of Information
Five studies [39,40,42-44] reported on enhancing availability
of general information on a digital care platform. In a
high-quality feasibility study [40], the option to receive
information was scored by patients with a mean of 7.1 (SD 1.5)
on a scale of 1-10. The actual usage of information sections in
the digital care platform differed among studies. One
high-quality study reported the patient EMR to be the most used
section of the digital care platform (mean 6.7, SD 4.7 logins
during the 4-month study period) [40] and another study of
moderate quality reported the opposite finding that the
information section was rarely viewed (mean 0.75, SD 1.4
number of times participants consulted the information section)
[39]. Needs of patients also differed, as Ruland et al [43]
reported a significant difference (625 vs 271, P=.01) in the
number of visits to the information section between breast cancer
and prostate cancer patients, with breast cancer patients visiting
this section more often. In this study, which was appraised as
low quality, information comprehensibility of the digital care
platform was rated with an overall mean score of 7.2 (SD 1.4)
and usefulness was rated with a mean score of 6.5 (SD 1.7),
both on a scale of 1-10 [43]. The main reasons for consulting
the general disease-related information section of the digital
care platform were to get help with problems and to get
assurance. In addition to the information section, the platform’s
ability to directly communicate with a nurse was perceived as
very useful, because it was perceived as easy-to-understand
information. The nurses’ contribution to a patient forum was
reported as a trustworthy source of information [43] and
therefore was highly valued by patients [44].
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Six studies investigated the effect of a digital care platform on
self-efficacy [37,38,40-42,44] and all of them reported positive
effects. Although the effects were not significant, a clear trend
toward a positive effect on self-efficacy was reported. In the
RCT performed by Børøsund et al [38], a moderate-quality
study, patients using a digital care platform tended to score
higher on self-efficacy compared with patients in the usual care
group (mean difference 8.81, range 33-297, 95% CI –0.92 to
18.53, P=.08). Patients reported that a digital care platform was
helpful in managing their health [44]. Groen et al [40] and
Kuijpers et al [42], studies with high to intermediate quality,
reported that access to general disease-related information and
patients’ EMRs enhanced patients’ knowledge of their disease
and their sense of control, based on questionnaires. Two RCTs
showed that using a digital care platform increased patients’
perceived ability to obtain and use health care information. The
digital care platform also increased their comfort and activation
level of dealing with physicians and health care situations
compared to the patient group only using the internet [37,41].
However, both of these RCTs were categorized as low quality.
Continuity of Care
None of the included clinical studies reported specifically on
continuity of care as a primary or secondary outcome parameter.
However, three low/intermediate-quality studies [38,39,43]
reported on the aspect of communication between patients and
HCPs and among HCPs within the platform. A
questionnaire-based pilot study [43] reported that the most
valued feature of the platform (ie, Webchoice) as expressed by
the study population was the ability to send messages to their
HCPs. That same research group investigated the effects of their
platform in an RCT and reported 40% use of the messaging
service in this platform [38]. Patients perceived this feature to
be useful and easy to understand. De Regge et al [39] reported
that HCPs perceived the ability to exchange research results
between HCPs (eg, HCPs in other hospitals and primary care)
as valuable to patient care and a means to optimize continuity
of care across institutes.
Patient- and HCP-Reported Experiences
Seven studies [37-40,42-44] reported on patient- or
HCP-reported experiences. Patient satisfaction with the studied
platform was considerably high in three
intermediate/high-quality studies, with a mean rating of 3.9
(range 3.8-4.09) on a 1-5 scale [39,40,42]. A low-quality RCT
that aimed to compare the effects of three different types of
interventions and one control observed significantly higher
patient satisfaction scores with their HCPs compared with those
of the control group at 6 weeks (3.46 vs 3.17, P=.01) and 6
months (3.48 vs 3.28, P=.03) [37]. The majority of patients
(75%-93%) stated that the platform was easy to use and that it
was a valuable addition to their health care experience [40,42].
The most used features of the platform varied among studies,
but mainly consisted of the personal medical records in
intermediate/high-quality studies [39,40,42]. Only two clinical
studies reported the experiences by HCPs. De Regge et al [39],
an intermediate-quality study, reported that HCPs perceived the
digital care platform as valuable compared to current care
because it provides reliable, easy-to-access information for
patients and because it enables the exchange of patient-related
information between care providers. Despite these positive
experiences, one-quarter of the physicians interviewed by
Kuijpers et al [42], an intermediate-quality study, reported an
increase in workload after installment of the digital care
platform, varying from a few extra minutes to more than 10
minutes per patient, for additional explanations on information
made available on the platform.
Barriers and Facilitators Levels
Overview
Table 2 presents the baseline characteristics of the studies
describing barriers and facilitators. Tables S1 and S2 in
Multimedia Appendix 1 present all barriers and facilitators
identified in the included studies. The most prominent barriers
and facilitators are discussed below. Figure 3 depicts the
illustrative quotations found in the studies for each level.
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Figure 3. Illustrative quotations mentioned in included studies concerning barriers (in red) and facilitators (in green) for implementation of a digital
platform.
Innovation Level
Four studies [44,46,48,51] described technical challenges as a
possible barrier for implementation. These included software
development, functionality of the website, bugs, and log-on and
internet access issues. A second barrier, concerning accessibility
of the innovation, was patients’ unawareness of the existence
of the digital care platform, which led to limited or no use of
the platform [53]. Despite these barriers, three studies showed
that the use of a digital care platform is feasible [40,42,44].
Facilitators in practice were numerous: access to general and
tailored medical information [42,45,47-49,52], full EMRs
[39,42,45-48,50-52], and educational materials [42,47].
Moreover, the possibility to consult HCPs through interactive
tools was mentioned to be a positive feature of a digital care
platform that encouraged usage [43,44,47,48,50].
Individual Professional Level
The most frequently described barrier at the professional level
was the concern of HCPs regarding the release of medical
information on the digital care platform and the
comprehensibility of medical jargon for patients
[39,45,46,48,49,51,52]. Patients learning about a change in their
health and well-being via a digital care platform was a fear
expressed by all oncologists included in two studies [45,48].
The second most frequently described barrier, described in seven
studies [39,42,45-47,49,51], concerned the fear of increased
workload such as an increased burden of documentation,
monitoring, and direct digital communication with patients
[39,42,45,49].
Concerning facilitators, one study suggested that a digital care
platform would not increase workload but would rather reduce
workload by easing data management [46]. Another facilitator
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mentioned was the ability to exchange information or medical
results between different HCPs, including those in primary care
such as general practitioners [39,46]. The optimization of data
exchange between institutes could avoid or reduce repeated
health assessments [46].
Patient Level
Three studies indicated that patients had concerns about the
readability of the information (medical jargon) displayed on the
digital care platform and whether medical results could be
adequately understood without professional interpretation
[45,46,48]. Some patients mentioned that this could increase
anxiety [48,52].
Facilitators at the patient level were numerous, as indicated in
Table S2 of Multimedia Appendix 1. In several studies, patients
and oncologists mentioned that patients having access to the
platform and their EMR could better prepare them for their
doctor visit and enabled them to take on an active role during
the consultation [45-47]. In addition, patients’ willingness to
communicate via digital resources facilitated implementation
[53]. Lastly, improved patient-doctor communication was
described as a facilitator, either by improved preparedness for
doctor visits or by direct messaging [52].
Social Context Level
Three studies reported concerns on how a digital care platform
could change the doctor-patient relationship [48] such as by
increasing the patient’s autonomous handling of information
[46]. The digital care platform could make patients increasingly
reliant on technology with decreased reliance on face-to-face
communication [46,49]. This was feared as it may negatively
influence the outpatient clinic visits as patients become more
focused on discussing (irrelevant) details regarding available
biomedical results rather than discussing values and preferences
important for a follow-up treatment [48].
The change of the doctor-patient relationship was also
mentioned as a facilitator. By enabling access to medical
information, patients could become more actively involved in
the management of their care and feel more comfortable to
interact with their HCPs during consultations [42,45].
Organizational Context Level
Two studies mentioned the integration of the platform into
existing systems as a barrier [44,47]. This would be especially
relevant in cases in which the digital care platforms were also
developed for other chronic diseases [47]. Limitations in time
and resources were reported as another type of barrier [44].
A clear facilitator at the organizational level was the digital care
platform’s ability to exchange important patient information
across health care institutes. HCPs emphasized the advantage
of a digital care platform in improving the cross-sectoral
availability of information about the patient to HCPs who are
involved in the patient’s treatment. It is suggested that the digital
care platform could thereby diminish information loss, be of
use in emergency situations where the rapid release of medical
information is vital, and avoid repeated diagnostic investigations
[46]. Organization of care could be improved as the improved
availability of information promotes cross-boundary continuity
of care and diminishes fragmentation of care [39,46]. Another
facilitator at the organizational level was the early introduction
of the digital care platform to the patient, preferably at diagnosis
[44], and sufficient instructions concerning appropriate use of
the platform for patients as well as HCPs [49].
Economic and Political Contexts Level
Data security and protection regarding the digital care platform
were concerns reported by numerous studies [46,50,51,53].
During the development of the digital care platform described
by Kildea et al [51], cybersecurity testing and legal issues were
the most time-consuming processes. These legal issues involved
the ownership of intellectual property [51] and liability [46,51].
Secure access was therefore identified as an important facilitator
for a digital care platform [48]. Another facilitator, in the
economical context, was that conferred by the optimized
exchange of patient information between institutes, enabled
with a digital care platform, and that unnecessary repeated




A digital care platform for oncological patients has the potential
to improve quality of care through the improved availability of
information and positive effect on self-efficacy. Although
continuity of care was not studied as a primary outcome in the
identified studies, based on focus group interviews with HCPs,
a digital care platform potentially improves continuity of care
by optimizing the exchange of patient information across
institutes. Patient-reported experiences such as satisfaction with
the platforms were considerably positive. Our barrier and
facilitator analysis indicated that the majority of barriers exist
at the professional level. This included a concern of increased
workload for HCPs and release of unattended medical
information to patients. The majority of facilitators were
identified at the patient and innovation levels. The patient’s
ability to become more informed, empowered, and involved in
their care was identified as a prominent facilitator. Another
relevant facilitator, at the organization level, is the digital care
platform’s potential to improve information exchange between
HCPs across different institutes. This is relevant as this may
improve continuity of care and diminish fragmentation of
oncological care. Among the clinical studies, the majority were
of low to intermediate quality. Regarding the barrier and
facilitator studies, the majority were of high quality.
The positive effects of a digital care platform described in this
review are consistent with prior research studying isolated
features of digital care platforms [16,29,54]. A digital care
platform seems to be a helpful medium in providing patients
with general disease-related and personal information. This is
a welcoming result as previous studies have described that a
considerable number of patients are dissatisfied with information
provision [55,56]. Moreover, 40%-80% of all medical
information provided by the HCP during a consultation is
forgotten or remembered incorrectly [57]. Therefore, the need
of patients to read or reread medical information that is relevant
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for their situation is an important facilitator for a digital care
platform. In this systematic review, we identified studies that
showed positive effects on self-efficacy, but no convincing
clinically significant effects. In another systematic review, which
studied the effectiveness of eHealth-based self-management
tools, significant yet small effects on self-efficacy were
described [25]. The authors explain that the tool was able to
increase self-efficacy by enabling patients to enhance
participation in their care trajectory. A more recent randomized
trial refuted this finding [58]. In this RCT, the effect of an
eHealth-based self-management tool (Oncokompas) was
investigated in 600 cancer patients. At 3 and 6 months, patients
were assessed on self-efficacy with the General Self-Efficacy
scale. No significant effects on self-efficacy were observed
(mean difference 0.5, 95% CI –0.4 to 1.4, P=.31). The authors
partially attributed the lack of effect to the included patient
population, which mostly consisted of patients diagnosed with
cancer 2 years prior to the study. The authors suggested that
this population is perhaps less in need of a self-management
tool to increase self-efficacy as they have more experience and
“know-how” compared with their newly diagnosed peers. The
hypothesis that the effect of an eHealth-based tool may vary
considerably depending on the patient population is important
to consider for assessing the effectiveness of a digital care
platform. In our systematic review, we included studies with
patients in different stages of their disease trajectory and with
different cancer types, and all effects regarding self-efficacy
were positive but not significant. On the one hand, this aspect
can be perceived as a limitation because the heterogeneity of
patients may underestimate the effect of a digital care platform.
On the other hand, it is a strength as we now have an overview
of the effect of a digital care platform on self-efficacy of a broad
cancer patient population, thereby increasing the generalizability
of our results.
Similarity with prior work concerns the limited number of
studies investigating combined features of a digital care
platform. During the screening process of this review, we
encountered numerous studies that only investigated one feature
of the platform. This finding is similar to the findings of a review
by Kruse et al [20], which concluded that many studies assessed
the effect of one feature of a digital care platform and that a full
platform was rarely studied in clinical practice. To adequately
ascribe outcomes as an effect of the intervention, it is reasonable
to first study an isolated feature of a digital care platform.
However, it is absolutely vital to also study the combined
features in a digital care platform for two key reasons: (1)
because this is likely to be the eHealth intervention that is
implemented in practice, and (2) because the effect of multiple
features may not be equivalent to the sum of effects of a single
feature.
The fact that we assessed the effects of digital care platforms
that had at least two key features can therefore be considered a
strength of this review. In addition, we assessed the effect of a
digital care platform on quality of care parameters such as
continuity of care, and described the patient- and HCP-related
experiences. Other reviews did not, and instead only assessed
the effect of a digital care platform with one feature or chose
to study different endpoints such as fatigue, physical activity,
depression, quality of life, and self-management abilities
[20,25,29,30,54,59]. An additional strength is that we analyzed
barriers and facilitators for implementation. This allows for a
good understanding of what is needed for successful
implementation. A final strength is that the search query was
quite elaborate without exclusion of non-English articles,
thereby minimizing the possibility of missing valuable studies.
For these reasons, this systematic review provides a
comprehensive overview of the best available evidence of the
effect of a digital care platform on quality of care for oncological
patients.
However, this systematic review also has some limitations.
First, the included clinical studies were mostly early-stage,
single-arm prospective studies where feasibility and
acceptability were investigated. Although we did include three
studies with a more advanced research methodology (ie, RCTs),
these studies were all appraised as studies with low to
intermediate quality. This makes interpretation of these RCTs
quite challenging. One RCT reported a significant difference
in patient satisfaction scores favoring a type of digital care
platform [37]; however, the minimal difference (3.48 vs 3.28
on a 1-5 scale) puts into question the clinical relevance of this
finding. A second limitation of this review concerns the
heterogeneity of study designs and of the digital care platforms.
Despite our predefined criteria of what a digital care platform
should include, they were still quite different from each other
with respect to the specific web format, options, and intended
use, among other aspects. This heterogeneity precluded a pooled
analysis with quantitatively measured outcome parameters. A
third limitation concerns the study population and its
representativeness. Three-quarters of the clinical studies
included breast cancer patients. This study population mainly
consists of well-educated females [60]. Indeed, 72%-73% of
the breast cancer population in the studies included in this
review had a college or university degree. It is plausible that a
high education is an important factor for successful use of a
digital care platform. For this reason, results of this review
should be interpreted with caution and cannot simply be
generalized to other cancer patients. A final limitation concerns
the barrier and facilitator analysis. Studies included in this
review almost exclusively focused on the barriers and facilitators
mentioned by the end users of the platform (ie, the patients and
HCPs). Evidently, their perspectives are crucial, but barriers
and facilitators proposed by other stakeholders should also be
investigated, such as stakeholders with an organizational,
economic, and political background (eg, health insurers). This
latter group can provide insight into what is required to realize
the structural financing of a digital care platform.
Although there is a growing body of literature that describes
the positive effects of digital care platforms, high-quality studies
describing the effectiveness of these platforms integrated in
oncological care are currently lacking. In addition, most studies
implemented a digital care platform in one target patient
population such as breast cancer patients. More evidence is
required concerning the desirability and use of a platform in
patients with other types of cancers and education levels. More
specifically, it is important to investigate whether patients with
a lower level of education can benefit from digital care platforms
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to the same extent as their well-educated peers to avoid widened
health disparities. The same applies to the patient population
with limited internet access or internet skills. Studies in this
review were performed in Australia, North America, and western
Europe. The usefulness of digital care platforms in countries
with low internet access is likely very different.
Concerning barriers and facilitators, future studies should aim
to further elucidate barriers and facilitators at the organizational
level and the economic and political levels. Ultimately, this is
required for a digital care platform to become a successful
eHealth-based tool in the improvement of quality of care for
patients living with cancer.
Conclusion
Digital care platforms have a favorable effect on availability of
information and enhancement of self-efficacy. Additionally,
they could potentially serve as a valuable medium to improve
continuity of care by optimizing communication between
patients and HCPs and among HCPs. The vast majority of
patients are positive about a digital care platform and its ability
to meet their needs in improving the availability of information
and patient involvement. Although these results are favorable,
they were mostly generated by early-stage, nonrandomized
studies with a specific patient population. To fully understand
whether a digital care platform is able to increase quality of care
by supporting the delivery of coordinated, patient-centered
oncological care, more advanced studies such as RCTs are
required, as well as studies investigating the barriers and
facilitators at the economic and political levels.
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